Arabilin overcomes resistance to AR-targeted therapy

被引：0
|
作者：
Takahiro Fujimaki
Shun Saito
Masaya Imoto
机构：
[1] Faculty of Science and Technology,Department of Biosciences and Informatics
[2] Keio University,undefined
来源：
The Journal of Antibiotics | 2017年 / 70卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：328 / 330
页数：2
相关论文
共 50 条
  • [31] PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
    McDermott, Martina S. J.
    Browne, Brigid C.
    Conlon, Neil T.
    O'Brien, Neil A.
    Slamon, Dennis J.
    Henry, Michael
    Meleady, Paula
    Clynes, Martin
    Dowling, Paul
    Crown, John
    O'Donovan, Norma
    MOLECULAR CANCER, 2014, 13
  • [32] PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
    Martina S J McDermott
    Brigid C Browne
    Neil T Conlon
    Neil A O’Brien
    Dennis J Slamon
    Michael Henry
    Paula Meleady
    Martin Clynes
    Paul Dowling
    John Crown
    Norma O’Donovan
    Molecular Cancer, 13
  • [33] Scheduling androgen deprivation with AR-targeted vaccination affects anti-tumor efficacy in prostate cancer
    Gamat-Huber, Melissa
    McNeel, Douglas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Bimodal Bone-Targeted Therapy Repairs Damage Bone and Overcomes Drug Resistance in Multiple Myeloma
    Sabol, Hayley
    Adhikari, Manish
    Ashby, Cody
    Anloague, Aric
    Kaur, Japneet
    Khan, Sharmin
    Palmieri, Michela
    Barnes, Lawry
    Ambrogini, Elena
    Srinivasan, Venkatesan
    Frontier, Alison
    Ebetino, Frank H.
    Delgado-Calle, Jesus
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 1 - 2
  • [35] Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
    Martina S. J. McDermott
    Brigid C. Browne
    Neil T. Conlon
    Neil A. O’Brien
    Dennis J. Slamon
    Michael Henry
    Paula Meleady
    Martin Clynes
    Paul Dowling
    John Crown
    Norma O’Donovan
    Molecular Cancer, 22
  • [36] Skin-targeted combinatorial DNA immunization overcomes tumor resistance to PD1 therapy
    Falo, Louis D.
    CANCER RESEARCH, 2020, 80 (16)
  • [37] FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
    Bernat-Peguera, Adria
    Navarro-Ventura, Juan
    Lorenzo-Sanz, Laura
    da Silva-Diz, Victoria
    Bosio, Mattia
    Palomero, Luis
    Penin, Rosa M.
    Perez Sidelnikova, Diana
    Oriol Bermejo, Josep
    Taberna, Miren
    Vilarino, Noelia
    Piulats, Josep M.
    Mesia, Ricard
    Maria Vinals, Joan
    Gonzalez-Suarez, Eva
    Capella-Gutierrez, Salvador
    Villanueva, Alberto
    Vinals, Francesc
    Munoz, Purificacion
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1491 - 1504
  • [38] The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Yamamura, Keisuke
    Okajima, Shigeo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [39] CHD-loss promotes tumor heterogeneity, lineage plasticity and resistance to AR targeted therapy resistance
    Mu, P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S22 - S23
  • [40] THE IMPORTANCE OF IMAGING STUDIES TO MONITOR TREATMENT WITH NOVEL AR-TARGETED AGENTS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC).
    Heidegger, Isabel
    Pfister, David
    Porres, Daniel
    Paffenholz, Pia
    Heidenreich, Axel
    JOURNAL OF UROLOGY, 2017, 197 (04): : E453 - E453
12345